Canton Strategic Holdings Stock
Canton Strategic Holdings Inc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Mark Wendland
- Employees
- 12
- Market cap
- $135 M
- IPO
- 12/01/2022
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging…
Canton Strategic Holdings stock: price history
1D
-9.4%
1W
-19.7%
1M
-16.9%
6M
-50.6%
YTD
-44.1%
1Y
-41.1%
2Y
-32.2%
5Y
–
10Y
–
Next earnings date
Next earnings date
16/11/2026 (in 30 days)
Volatility around earnings
~9% weaker price swings than usual
Ask the agents about Canton Strategic Holdings
Analyst assessment of Canton Strategic Holdings
0
STRONG BUY
0
BUY
1
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Hold
As of: 16/07/2023
Canton Strategic Holdings stock metrics
P/E
-1.08
P/B
0.81
EV/EBITDA
-1.32
RETURN ON EQUITY
-4.2%
NET MARGIN
-1,287.2%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
87.2%
FLOAT SHARES
69,463,023
AVG. DAILY VOLUME (30D)
871,220
Insider transactions (SEC)
Stetz Gary S.
Stetz Gary S.
Stetz Gary S.
Stetz Gary S.
Stetz Gary S.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Canton Strategic Holdings stock
What does Canton Strategic Holdings do?
Canton Strategic Holdings Inc is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Mark Wendland, the company employs around 12 people.
The IPO was on 12/01/2022; the stock trades on NASDAQ under the ticker CNTN.
What do analysts say about Canton Strategic Holdings stock?
1 analysts rate the stock, the consensus is Hold (as of 16/07/2023).
This is an external assessment, not a statement by Market Jury.
When does Canton Strategic Holdings report next?
The next earnings date is 16/11/2026.
Around past earnings, price swings were roughly -9% stronger than usual.
Does Canton Strategic Holdings pay a dividend?
No, Canton Strategic Holdings currently does not pay a dividend.
Which stocks are comparable to Canton Strategic Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Canton Strategic Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Canton Strategic Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.